To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Cost and committee reports

Official records Congress.gov attaches to H.R. 3839.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Mr. DUNN of Florida, as printed in the Congressional Record (Vol. 169, No. 98, June 6, 2023, Page H2763):
  Article I, Section 8, clause 3 provides Congress with the power ``to regulate commerce with foreign nations, and among the several states, and with the Indian tribes.'' The single subject of this legislation is: This bill alters the FDA review process for complex generic drug applications.
  Source: Congress.gov, Congressional Record June 6, 2023 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  290 characters

  Congress.gov bill record

  H.R. 3839, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/3839

  Record last updated by Congress.gov

  July 24, 2024

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  ab6fb8b42cd76b10b0667838b86d6a2e317b7dd34e40a53568fbc54135706679

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of July 24, 2024). Not every bill gets one.

From the Congress.gov bill record for H.R. 3839, last updated July 24, 2024. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.